{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:57:55Z","timestamp":1782449875950,"version":"3.54.5"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Parkinson\u2019s disease (PD) is the second most common neurodegenerative disorder with prominent dopamine (DA) neuron degeneration. PD affects millions of people worldwide, but currently available therapies are limited to temporary relief of symptoms. As an effort to discover disease-modifying therapeutics, we have conducted a screen of 1,403 bioactive small molecule compounds using an <jats:italic>in vivo<\/jats:italic> whole organism screening assay in transgenic larval zebrafish. The transgenic model expresses the bacterial enzyme nitroreductase (NTR) driven by the tyrosine hydroxylase (th) promotor. NTR converts the commonly used antibiotic pro-drug metronidazole (MTZ) to the toxic nitroso radical form to induce DA neuronal loss. 57 compounds were identified with a brain health score (BHS) that was significantly improved compared to the MTZ treatment alone after FDR adjustment (padj&amp;lt;0.05). Independently, we curated the high throughput screening (HTS) data by annotating each compound with pharmaceutical classification, known mechanism of action, indication, IC50, and target. Using the Reactome database, we performed pathway analysis, which uncovered previously unknown pathways in addition to validating previously known pathways associated with PD. Non-topology-based pathway analysis of the screening data further identified apoptosis, estrogen hormone, dipeptidyl-peptidase 4, and opioid receptor Mu1 to be potentially significant pathways and targets involved in neuroprotection. A total of 12 compounds were examined with a secondary assay that imaged DA neurons before and after compound treatment. The z\u2019-factor of this secondary assay was determined to be 0.58, suggesting it is an excellent assay for screening. Etodolac, nepafenac, aloperine, protionamide, and olmesartan showed significant neuroprotection and was also validated by blinded manual DA neuronal counting. To determine whether these compounds are broadly relevant for neuroprotection, we tested them on a conduritol-b-epoxide (CBE)-induced Gaucher disease (GD) model, in which the activity of <jats:italic>glucocerebrosidase<\/jats:italic> (GBA), a commonly known genetic risk factor for PD, was inhibited. Aloperine, olmesartan, and nepafenac showed significant protection of DA neurons in this assay. Together, this work, which combines high content whole organism <jats:italic>in vivo<\/jats:italic> imaging-based screen and bioinformatic pathway analysis of the screening dataset, delineates a previously uncharted approach for identifying hit-to-lead candidates and for implicating previously unknown pathways and targets involved in DA neuron protection.<\/jats:p>","DOI":"10.3389\/fphar.2022.837756","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T06:37:12Z","timestamp":1647585432000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["In Vivo Dopamine Neuron Imaging-Based Small Molecule Screen Identifies Novel Neuroprotective Compounds and Targets"],"prefix":"10.3389","volume":"13","author":[{"given":"Gha-hyun J.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meri","family":"Okorie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiashun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Arkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and Treatment of Parkinson Disease: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1021\/jacs.9b00056","article-title":"Functionalized Cyclophellitols Are Selective Glucocerebrosidase Inhibitors and Induce a Bona Fide Neuropathic Gaucher Model in Zebrafish","volume":"141","author":"Artola","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"B3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/157015910790909485","article-title":"Cyclooxygenase and Neuroinflammation in Parkinson's Disease Neurodegeneration","volume":"8","author":"Bartels","year":"2010","journal-title":"Curr. Neuropharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/jamaneurol.2014.65","article-title":"Sleep and Circadian Rhythm Regulation in Early Parkinson Disease","volume":"71","author":"Breen","year":"2014","journal-title":"JAMA Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1468-1331.2009.02848.x","article-title":"Expression of Clock Genes Per1 and Bmal1 in Total Leukocytes in Health and Parkinson's Disease","volume":"17","author":"Cai","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/nprot.2008.58","article-title":"Nitroreductase-mediated Cell\/tissue Ablation in Zebrafish: a Spatially and Temporally Controlled Ablation Method with Applications in Developmental and Regeneration Studies","volume":"3","author":"Curado","year":"2008","journal-title":"Nat. Protoc."},{"key":"B7","first-page":"504","article-title":"Parkinson\u2019s Disease and its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis","volume":"40","author":"DeMaagd","year":"2015","journal-title":"P. T."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e26557","DOI":"10.7554\/eLife.26557","article-title":"Bmal1 Function in Skeletal Muscle Regulates Sleep","volume":"6","author":"Ehlen","year":"2017","journal-title":"Elife"},{"key":"B9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature12111","article-title":"The Zebrafish Reference Genome Sequence and its Relationship to the Human Genome","volume":"496","author":"Howe","year":"2013","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"842","DOI":"10.2337\/dc06-2011","article-title":"Type 2 Diabetes and the Risk of Parkinson's Disease","volume":"30","author":"Hu","year":"2007","journal-title":"Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1523\/JNEUROSCI.2551-14.2015","article-title":"Circadian Modulation of Dopamine Levels and Dopaminergic Neuron Development Contributes to Attention Deficiency and Hyperactive Behavior","volume":"35","author":"Huang","year":"2015","journal-title":"J. Neurosci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/brain\/awx364","article-title":"A Novel Metabolism-Based Phenotypic Drug Discovery Platform in Zebrafish Uncovers HDACs 1 and 3 as a Potential Combined Anti-seizure Drug Target","volume":"141","author":"Ibhazehiebo","year":"2018","journal-title":"Brain"},{"key":"B13","doi-asserted-by":"publisher","first-page":"107860","DOI":"10.1016\/j.neuropharm.2019.107860","article-title":"Modifying the Progression of Alzheimer's and Parkinson's Disease with Deep Brain Stimulation","volume":"171","author":"Jakobs","year":"2020","journal-title":"Neuropharmacology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson\u2019s Disease: Etiopathogenesis and Treatment","volume":"91","author":"Jankovic","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e69795","DOI":"10.7554\/eLife.69795","article-title":"A Zebrafish Screen Reveals Renin-Angiotensin System Inhibitors as Neuroprotective via Mitochondrial Restoration in Dopamine Neurons","volume":"10","author":"Kim","year":"2021","journal-title":"Elife"},{"key":"B16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nrn.2017.75","article-title":"Animal Models of \u03b1-synucleinopathy for Parkinson Disease Drug Development","volume":"18","author":"Koprich","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cbpa.2019.02.005","article-title":"Developing Zebrafish Disease Models for In Vivo Small Molecule Screens","volume":"50","author":"Lam","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0164645","DOI":"10.1371\/journal.pone.0164645","article-title":"A High-Content Larval Zebrafish Brain Imaging Method for Small Molecule Drug Discovery","volume":"11","author":"Liu","year":"2016","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e2005970","DOI":"10.1371\/journal.pbio.2005970","article-title":"CellProfiler 3.0: Next-Generation Image Processing for Biology","volume":"16","author":"McQuin","year":"2018","journal-title":"PLOS Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrd.2017.111","article-title":"Opportunities and Challenges in Phenotypic Drug Discovery: An Industry Perspective","volume":"16","author":"Moffat","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B21","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/cpt.1548","article-title":"N-Acetyl Cysteine Is Associated with Dopaminergic Improvement in Parkinson's Disease","volume":"106","author":"Monti","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/biom10020335","article-title":"The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers","volume":"10","author":"Paolini Paoletti","year":"2020","journal-title":"Biomolecules"},{"key":"B23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11910-018-0829-3","article-title":"Mitochondrial Dysfunction in Parkinson's Disease: New Mechanistic Insights and Therapeutic Perspectives","volume":"18","author":"Park","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-1-60327-977-2_9","article-title":"Nitroreductase-mediated Cell Ablation in Transgenic Zebrafish Embryos","volume":"546","author":"Pisharath","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/cells8040364","article-title":"GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches","volume":"8","author":"Riboldi","year":"2019","journal-title":"Cells"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1742-2094-1-6","article-title":"Selective COX-2 Inhibition Prevents Progressive Dopamine Neuron Degeneration in a Rat Model of Parkinson's Disease","volume":"1","author":"S\u00e1nchez-Pernaute","year":"2004","journal-title":"J. Neuroinflammation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3390\/jcm9041061","article-title":"Impact of Natural Compounds on Neurodegenerative Disorders: From Preclinical to Pharmacotherapeutics","volume":"9","author":"Sharifi-Rad","year":"2020","journal-title":"J. Clin. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.3892\/etm.2018.5896","article-title":"Aloperine Activates the Nrf2-ARE Pathway when Ameliorating Early Brain Injury in a Subarachnoid Hemorrhage Model","volume":"15","author":"Song","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"D939","DOI":"10.1093\/nar\/gkaa980","article-title":"Genenames.org: the HGNC and VGNC Resources in 2021","volume":"49","author":"Tweedie","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/path.4751","article-title":"Delineating Pathological Pathways in a Chemically Induced Mouse Model of Gaucher Disease","volume":"239","author":"Vardi","year":"2016","journal-title":"J. Pathol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"D1031","DOI":"10.1093\/nar\/gkz981","article-title":"Therapeutic Target Database 2020: Enriched Resource for Facilitating Research and Early Development of Targeted Therapeutics","volume":"48","author":"Wang","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1042\/BJ20150650","article-title":"Nitroreductase Gene-Directed Enzyme Prodrug Therapy: Insights and Advances toward Clinical Utility","volume":"471","author":"Williams","year":"2015","journal-title":"Biochem. J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.bbrc.2014.08.025","article-title":"Aloperine Attenuated Neuropathic Pain Induced by Chronic Constriction Injury via Anti-oxidation Activity and Suppression of the Nuclear Factor Kappa B Pathway","volume":"451","author":"Xu","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41531-020-0117-1","article-title":"Current and Projected Future Economic burden of Parkinson's Disease in the U.S","volume":"6","author":"Yang","year":"2020","journal-title":"NPJ Parkinsons Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e57245","DOI":"10.7554\/eLife.57245","article-title":"Large-scale Phenotypic Drug Screen Identifies Neuroprotectants in Zebrafish and Mouse Models of Retinitis Pigmentosa","volume":"10","author":"Zhang","year":"2021","journal-title":"Elife"},{"key":"B36","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1177\/1087057107300646","article-title":"The Use of Strictly Standardized Mean Difference for Hit Selection in Primary RNA Interference High Throughput Screening Experiments","volume":"12","author":"Zhang","year":"2007","journal-title":"J. Biomol. Screen."},{"key":"B37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.biopha.2018.09.008","article-title":"Neuro-protective Effects of Aloperine in an Alzheimer's Disease Cellular Model","volume":"108","author":"Zhao","year":"2018","journal-title":"Biomed. Pharmacother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.837756\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T06:37:14Z","timestamp":1647585434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.837756\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":37,"alternative-id":["10.3389\/fphar.2022.837756"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.837756","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"article-number":"837756"}}